Tag: optimization

Harness the power of AI-optimized smart contracts with PFMCrypto—now supporting seamless XRP cloud mining alongside BTC, ETH, DOGE, and USDC for consistent, diversified returns delivered daily.

HUNTSVILLE, AL, July 10, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company advancing its lead IND candidate SER-252 for advanced Parkinson's disease, enabled by its proprietary POZ Platform^™ drug optimization technology, announced that it has made a grant of options to purchase an aggregate of 12,500 shares of Serina’s common stock to a new non-executive employee on June 18, 2025 (the “Option Grant”).

CALGARY, Alberta, July 10, 2025 (GLOBE NEWSWIRE) -- Gibson Energy Inc. (TSX:GEI) (“Gibson” or the “Company”) announced today that it expects to release its 2025 second quarter financial and operating results on Monday, July 28, 2025, after the close of North American markets. The 2025 second quarter management's discussion and analysis and unaudited consolidated financial statements will be available on the Company's website at www.gibsonenergy.com and on SEDAR+ at www.sedarplus.ca.

FREMONT, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Enphase Energy, Inc. (NASDAQ: ENPH), a global energy technology company and the world's leading supplier of microinverter-based solar and battery systems, today announced that production shipments of its newest electric vehicle (EV) charger, the IQ^® EV Charger 2, have expanded across Europe to now include Greece, Romania, Ireland, and Poland. The IQ EV Charger 2 is a smart charger designed to work seamlessly with Enphase solar and battery systems or as a powerful standalone charger. Additionally, in France, the IQ EV Charger 2 has received one of the country’s highest quality standards, the E.V. READY certification, and can now integrate with the “Linky” meter to enable dynamic load balancing for standalone charger installations.

CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the formation of its dedicated clinical team and the expansion of its research team. These developments represent a significant milestone in the company’s ongoing progress in advancing its RNA-based immunotherapies, known as CryptiVax™, into clinical trials.